Patents Examined by David S. Romeo
  • Peptidoglycan recognition proteins and their production
    Patent number: 6413729
    Abstract: A gene coding for a peptidoglycan recognition peptide (PGRP) is cloned, a recombinant vector into which said gene is introduced is obtained, and a transformant transformed with said recombinant vector is cultivated, thereby producing the PGRP in large amounts at high purity.
    Type: Grant
    Filed: August 16, 1999
    Date of Patent: July 2, 2002
    Assignee: Wako Pure Chemical Industries, Inc.
    Inventors: Masaaki Ashida, Masanori Ochiai, Masakazu Tsuchiya
  • Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis
    Patent number: 6410269
    Abstract: Vitamin D-binding protein (Gc protein) and its small domain (approximately ⅕ of the Gc peptide also known as domain III) were cloned via a baculovirus vector. The cloned Gc protein and the cloned domain (Cd) peptide were treated with immobilized &bgr;-galactosidase and sialidase to yield macrophage activating factors, GcMAFc and CdMAF, respectively. These cloned macrophage activating factors and GcMAF are to be used for therapy of cancer, HIV-infection and osteopetrosis, and may also be used as adjuvants for immunization and vaccination.
    Type: Grant
    Filed: March 19, 1996
    Date of Patent: June 25, 2002
    Inventor: Nobuto Yamamoto
  • Morphogen treatments for limiting proliferation of epithelial cells
    Patent number: 6399569
    Abstract: Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation normally associated with ulcerative diseases, and (4) stimulating the repair of ulcerative lesions and the regeneration of the luminal tissue. The methods and compositions include a therapeutically effective amount of a morphogen as defined herein.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: June 4, 2002
    Assignee: Curis, Inc.
    Inventors: Charles M. Cohen, Marc F. Charette, Thangavel Kuberasampath, David C. Rueger, Hermann Oppermann, Roy H. L. Pang, Engin Ozkaynak, John E. Smart
  • Recombinant streptavidin-metallothionein chimeric protein having biological recognition specificity
    Patent number: 6391590
    Abstract: Streptavidin-metallothionein chimeric proteins with biological recognition specificity in which the streptavidin moiety provides high affinity biotin binding and the metallothionein moiety provides a high affinity metal binding. The binding affinity of the streptavidin-metallothionein chimeric protein both for biotin and heavy metal ions allows specific incorporation into, conjugation with, or labelling of any biological material containing biotin with various heavy metal ions.
    Type: Grant
    Filed: October 21, 1991
    Date of Patent: May 21, 2002
    Assignee: The Regents of the University of California
    Inventors: Takeshi Sano, Alexander N. Glazer, Charles R. Cantor
  • Motilin homologs
    Patent number: 6380158
    Abstract: The present invention is directed to polynucleotides, polypeptides and uses thereof for a novel CDNA sequence which has homology to motilin. Tissue distribution of the mRNA for the novel polypeptide is specific to the stomach, small intestine and pancreas. The present invention further includes agonists, antagonists, antibodies and host cells expressing the cDNA encoding the novel motilin homologs.
    Type: Grant
    Filed: March 24, 1997
    Date of Patent: April 30, 2002
    Assignee: ZymoGenetics, Inc.
    Inventor: Paul O. Sheppard
  • Lipopolysaccharide binding protein derivatives
    Patent number: 6376462
    Abstract: Disclosed are novel biologically active lipopolysaccharide binding protein (LBP) derivatives including LBP derivative hybrid proteins which are characterized by the ability to bind to and neutralize LPS and which lack the CD14-mediated immunostimulatory properties of holo-LBP.
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: April 23, 2002
    Assignee: Xoma Corporation
    Inventors: Héle{overscore (n)}e Gazzano-Santoro, Georgia Theofan, Patrick W. Trown
  • Water-soluble polypeptides
    Patent number: 6372890
    Abstract: In this invention there are provided a polypeptide having morphogenesis-accelerating activity or cell-proliferating activity against epithelial cells, said polypeptide being defined by the 1st to 103rd amino acids from the N-terminal of human epimorphin or being defined by the 1st to 104th amino acids from the N-terminal of murine epimorphin, and a medicament containing said polypeptide as an effective ingredient. Such polypeptides are soluble in water and are useful as the effective ingredients of medicaments for the treatment or prevention of diseases involving the aberration of morphogenesis, such as inflammatory disorders, burn or wound, and as those of medicaments for use in hair growth promotion.
    Type: Grant
    Filed: May 18, 1999
    Date of Patent: April 16, 2002
    Assignee: Sumitomo Electric Industries, Ltd.
    Inventor: Shogo Koshida
  • Peptide fragments and analogs derived from PBAN 1-33 NH2 for controlling moths
    Patent number: 6358927
    Abstract: Synthetic peptide fragments from pheromone biosynthesis activating neuropeptide PBAN (1-33)-NH2 of Helicoverpa zea which have either pheromone biosynthesis stimulating or inhibiting activity.
    Type: Grant
    Filed: December 18, 1996
    Date of Patent: March 19, 2002
    Assignee: State of Israel
    Inventor: Miriam Altstein
  • Bone morphogenetic proteins and their use in bone growth
    Patent number: 6352972
    Abstract: A bone morphogenetic fusion protein and a method of preparation of the bone morphogenetic fusion protein. The bone morphogenetic fusion protein comprises a purification tag and a bone morphogenetic active fragment. A method of preparing bone morphogenetic fusion protein comprises purifying and renaturing bone morphogenetic protein to provide an active bone morphogenetic fusion protein preparation. Methods of use of the bone morphogenetic fusion protein are also provided.
    Type: Grant
    Filed: June 3, 1997
    Date of Patent: March 5, 2002
    Inventors: Marcel E. Nimni, Frederick L. Hall, Lingtau Wu, Bo Han, Edwin C. Shors
  • Compositions and methods for enhancing osseous growth, repair and regeneration
    Patent number: 6350867
    Abstract: Novel human DLX3 genes and their encoded proteins are provided herein. The proteins encoded by the disclosed DLX3 and DLX3&Dgr; genes play a pivotal role in craniofacial growth and development. DLX3 genes and their encoded proteins provide valuable therapeutic targets for the design of proliferative agents which augment bone growth and repair.
    Type: Grant
    Filed: February 27, 1998
    Date of Patent: February 26, 2002
    Assignee: Wake Forest University
    Inventors: Thomas C. Hart, Jennifer A. Price
  • Corticotropin release inhibiting factor and methods of using same
    Patent number: 6348571
    Abstract: The invention includes a substantially pure preparation of a corticotropin release inhibiting factor (CRIF) peptide having from three to twenty one or to twenty five contiguous amino acids contained within the amino acid sequence positioned between the fourth and fifth TRH sequence on a prepro-TRH protein.
    Type: Grant
    Filed: August 3, 1999
    Date of Patent: February 19, 2002
    Assignees: Northwestern University, The Trustees of the University of Pennsylvania
    Inventors: Eva Redei, Fraser Aird
  • Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
    Patent number: 6346388
    Abstract: The present invention relates to tumor necrosis factor receptor (TNF-R) related polypeptides and their ligands, hereinafter referred to as TR1, TR2, TL2 and TL4. The invention relates to methods to identify agonists and antagonists of TR1, TR2, TL2 and TL4.
    Type: Grant
    Filed: May 6, 1998
    Date of Patent: February 12, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: Michael R. Brigham-Burke, Peter R. Young
  • Human C3b/C4b receptor (CR1)
    Patent number: 6316604
    Abstract: The present invention relates to the C3b/C4b receptor (CR1) gene and its encoded protein. The invention also relates to CR1 nucleic acid sequences and fragments thereof comprising 70 nucleotides and their encoded peptides or proteins comprising 24 amino acids. The invention further provides for the expression of the CR1 protein and fragments thereof. The genes and proteins of the invention have uses in diagnosis and therapy of disorders involving complement activity, and various immune system or inflammatory disorders. In specific embodiments of the present invention detailed in the examples sections infra, the cloning, nucleotide sequence, and deduced amino acid sequence of a full-length CR1 cDNA and fragments thereof are described. The expression of the CR1 protein and fragments thereof is also described. Also described is the expression of a secreted CR1 molecule lacking a transmembrane region.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 13, 2001
    Assignee: Avant Immunotherapeutics, Inc.
    Inventors: Douglas T. Fearon, Lloyd B. Klickstein, Winnie W. Wong, Gerald R. Carson, Michael F. Concino, Stephen H. Ip, Savvas C. Makrides, Henry C. Marsh, Jr.
  • Antibodies to motilin homologs
    Patent number: 6291653
    Abstract: The present invention is directed to polynucleotides, polypeptides and peptide fragments thereof, and uses thereof for a novel cDNA sequence which has homology to motilin. Tissue distribution of the mRNA for the novel polypeptide is specific to the stomach, small intestine and pancreas. The present invention further includes agonists, antagonists, antibodies, host cells expressing the cDNA encoding the novel motilin homologs and methods for increasing gastric motility using the novel molecules.
    Type: Grant
    Filed: March 23, 1998
    Date of Patent: September 18, 2001
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Theresa A. Deisher
  • Transforming growth factor Alpha HI
    Patent number: 6265543
    Abstract: The present invention discloses transforming growth factor alpha HI polypeptides and polynucleotides encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and therapeutic uses of the polypeptides which include stimulating wound healing, treating neurological disorders, treating ocular disorders, treating kidney and liver disorders and stimulating embryogenesis and angiogenesis. Also disclosed are antagonists against such polypeptide and their use as a therapeutic to treat neoplasia. Also disclosed are diagnostic assays for detecting altered levels of the polypeptide of the present invention and mutations in the nucleic acid sequences which encode the polypeptides of the present invention.
    Type: Grant
    Filed: August 20, 1997
    Date of Patent: July 24, 2001
    Assignee: Human Genome Sciences, Inc.
    Inventors: Paul S. Meissner, Rebecca A. Fuldner, Ying Fei-Wei, Mark D. Adams
  • BMP-4 products
    Patent number: 6245889
    Abstract: Purified BMP-2 and BMP-4 proteins and processes for producing them are disclosed. The proteins may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.
    Type: Grant
    Filed: September 9, 1997
    Date of Patent: June 12, 2001
    Assignee: Genetics Institute, Inc.
    Inventors: Elizabeth A. Wang, John M. Wozney, Vicki A. Rosen
  • Immunoassay of human growth hormone with a molecular weight of about 20,000
    Patent number: 6235490
    Abstract: An animal cell capable of producing an antibody specific to a human growth hormone having a molecular weight of 20,000 (20 k hGH) was prepared from an animal immunized with 20 k hGH. The animal cell was fused with a myeloma cell to produce a monoclonal antibody which specifically reacted to 20 k hGH, but substantially not to 22 k hGH. The monoclonal antibody was useful for immunoassay of 20 k hGH.
    Type: Grant
    Filed: October 29, 1998
    Date of Patent: May 22, 2001
    Assignee: Mitsui Chemicals, Inc.
    Inventors: Ichiro Ikeda, Naoko Kono, Tadashi Makino, Yoshihide Hashimoto
  • Polypeptides their production and use
    Patent number: 6228984
    Abstract: The present invention relates to the ligand polypeptide for the human pituitary- and mouse pancreas-derived G protein-coupled receptor proteins. The ligand polypeptide or the DNA which codes for the ligand polypeptide can be used for (1) development of medicines such as pituitary function modulators, central nervous system function modulators, and pancreatic function modulators, and (2) development of recombinant receptor proteins and screening of pharmaceutical candidate compounds. In particular, by the receptor binding assay systems utilizing the expression of recombinant G protein-coupled receptor proteins in accordance with the invention, agonists and antagonists of G protein-coupled receptors which are specific to human and other warm-blooded animals can be screened and the agonists or antagonists obtained can be used as therapeutic and prophylactic agents for various diseases.
    Type: Grant
    Filed: February 7, 1997
    Date of Patent: May 8, 2001
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Shuji Hinuma, Yugo Habata, Yuji Kawamata, Masaki Hosoya, Ryo Fujii, Shoji Fukusumi, Chieko Kitada
  • Fibroblast stimulating growth factor 1 (FsF-1) and the early detection of fibrosis
    Patent number: 6214968
    Abstract: A method for identifying individuals with a propensity for pathological fibrosis. The method involves providing a sample from an individual with a chronic inflammatory disease, contacting the sample with an antibody specific for fibroblast stimulating factor-1 (FsF-1) under conditions which permit immunocomplex formation, and detecting an increase in the relative level of the immunocomplex as an indication of a propensity for pathological fibrosis. FsF-1 polypeptides and antibodies specific for FsF-1, and DNA sequences encoding FsF-1 polypeptides are also disclosed.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: April 10, 2001
    Assignee: New England Medical Center Hospitals, Inc.
    Inventors: David J. Wyler, Sadhana Prakash, Xiaoping Zhang
  • Monoclonal antibody specific for 20K human growth hormone and a cell line producing the monoclonal antibody
    Patent number: 6197938
    Abstract: An animal cell capable of producing an antibody specific to a human growth hormone having a molecular weight of 20,000 (20 k hGH) was prepared from an animal immunized with 20 k hGH. The animal cell was fused with a myeloma cell to produce a monoclonal antibody which specifically reacted to 20 k hGH, but substantially not to 22 k hGH. The monoclonal antibody was useful for immunoassay of 20 k hGH.
    Type: Grant
    Filed: June 13, 1997
    Date of Patent: March 6, 2001
    Assignee: Mitsui Chemicals, Incorporated
    Inventors: Ichiro Ikeda, Naoko Kono, Tadashi Makino, Yoshihide Hashimoto